The company said that the purpose of the Innovation Credit is to reduce the financial risk for entrepreneurs and, as such, repayment of the credit, contributing 35% of the total project budget of EUR 3.8m, is subject to the commercial success of the project.
InteRNA CEO Roel Schaapveld said that they are very pleased to receive this funding for the melanoma program as it recognises the innovative character and commercial outlook of this project, a prerequisite to qualify for this facility.
"It allows us to further strengthen the R&D team and speed up the development of our miRNA-based therapy to treat more advanced stages of this aggressive form of cancer for which there currently is no adequate treatment," Schaapveld said.